

## Treatment of Breast Cancer

---

Reference Number: RDF1895-23

Date of Response: 06/10/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

*Royal Devon University Healthcare NHS Foundation Trust,*

*I am conducting analysis on the treatment of breast cancer in secondary care and kindly request your help.*

*I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of Jun 2023 to the end of Aug 2023, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.*

*1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023\*?*

Total: Please see table below.

<b>Drug Name</b>	<b>Total</b>
Abemaciclib (Verzenios)	22
Alpelisib (Piqray)	≤5
Fulvestrant (fulvestrant or Faslodex)	24
Palbociclib (Ibrance)	63
Ribociclib (Kisqali)	40

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

*2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023\*?*

Answer: Nil.

*3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023\*?*

Answer: 21.

*4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023\*?*

Answer: Please see table below.

<b>Treatment intent</b>	<b>Total Number of Patients</b>
Curative	≤5
Palliative	≤5
Not known / stated	17

Please note: All data above is based on latest available SACT data, from 01 April 2023 to 30 June 2023.